Galena Biopharma fka GALE

[MDMSCF]

I'm not sure it is fact that there was/is a high drop out rate for patients in Ukraine. What we know for sure is about half of the Ukraine clinical sites have withdrawn from the trial. There is a big difference between drop outs and a site withdrawn. There are essentially no side effects with NeuVax other than the local immune reaction at the site of dosing, so I have trouble believing drop outs are high. My models have been updated a few times since last fall more so to reflect a slightly slower enrollment pace. Which has more to do with the requirements for a patient to be eligible for entry into the trial versus not enough clinical sites, available patients or drop out rates.